GREAT NECK, NEW YORK - 07/21/2016 (PRESS RELEASE JET) — Sarraf Gentile LLP announces that it is investigating claims on behalf of investors in Revance Therapeutics, Inc. (NASDAQ: RVNC).
A class action lawsuit was filed against the company alleging that the Registration Statement issued in connection with the company’s June 19, 2014 follow-on public stock offering failed to disclose, among other things, that Revance: (i) had not commenced a Phase 3 clinical trial of RT0001—its lead product under development for the treatment of wrinkles around the eyes—in the first quarter of 2014; and, (ii) did not have the quality or quantity of RT001 to complete a Phase 3 clinical trial.
If you are a current Revance shareholder and want to discuss your legal rights, at no cost and without obligation, please contact Joseph Gentile at Sarraf Gentile LLP (telephone: 516-699-8890, extension 12; e-mail: firstname.lastname@example.org).
Sarraf Gentile LLP has extensive experience litigating shareholder actions across the United States and has recovered millions of dollars on behalf of injured shareholders.
ATTORNEY ADVERTISING. Prior results do not guarantee a similar outcome.
SARRAF GENTILE LLP
14 Bond Street, Suite 212
Great Neck, NY 11021
Media Contacts:Company Name: Sarraf Gentile LLP